Interactions of antithrombin and proteins in the plasma contact activation system with immobilized functional heparin

Journal of Biomedical Materials Research - Part A

Volumn 67, Issue 2, 2003, Pages 475-483

  Cornelius, Rena M ^a   Sanchez, Javier ^b   Olsson, Per ^b   Brash, John L ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Antithrombin; Heparinized surface; Immunoblot; Intrinsic coagulation; Protein adsorption; SDS PAGE

Indexed keywords

ADSORPTION; BIOASSAY; ELECTROPHORESIS; POLYETHYLENES; PROTEINS;

IMMUNOBLOTS;

BIOMEDICAL ENGINEERING;

ANTITHROMBIN; BIOMATERIAL; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 12A; HEPARIN; KALLIKREIN; POLYETHYLENE; PROTEIN;

ADSORPTION; ADULT; ARTICLE; BLOOD CLOTTING; CONTACT INHIBITION; CONTROLLED STUDY; ELUTION; ENZYME ASSAY; HEPARINIZATION; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; MATERIAL COATING; NONHUMAN; NORMAL HUMAN; PLASMA; PLASMA CONTACT ACTIVATION SYSTEM; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN IMMOBILIZATION; PROTEIN INTERACTION; SURFACE PROPERTY;

EID: 0346753841     PISSN: 00219304     EISSN: None     Source Type: Journal    
DOI: 10.1002/jbm.a.10118     Document Type: Article

References (48)

1. Salzman E, Merrill EW, Kent K. Interaction of blood with artificial surfaces. In: Bloom AL, Forbes CD, Thomas DP, Tuddenham EGD, editors. Haemostasis and thrombosis. Edinburgh: Churchill Livingstone; 1994. p 1469-1485.
2. Saito H. The contact phase of blood coagulation. In: Bloom AL, Forbes CD, Thomas DP, Tuddenham EGD, editors. Haemostasis and thrombosis. Edinburgh: Churchill Livingstone; 1994. p 289-307.
3. Sanchez J, Elgue G, Riesenfeld J, Olsson P. Inhibition of the plasma contact activation system of immobilized heparin: relation to surface density of functional antithrombin binding sites. J Biomed Mater Res 1997;37:37-42.
4. Sanchez J, Elgue G, Riesenfeld J, Olsson P. Studies of adsorption, activation, and inhibition of factor XII on immobilized heparin. Thromb Res 1998;89:41-50.
5. Sanchez J, Olsson P. On the control of plasma contact activation system on the human endothelium. Comparisons with an end-point attached heparin surface. Thromb Res 1999;93:27-34.
6. Bindslev L, Gouda I, Inacio J, Kodama K, Lagergren H, Nilsson LOE, Olsson P. Extracorporeal elimination of carbon dioxide using a surface-heparinized veno-venous bypass system. Trans Am Soc Artif Inter Organs 1986;32:530-533.
7. Borowiec J, Thelin S, Bagge L, Hultman J, Hansson HE. Decreased blood loss after cardiopulmonary bypass using heparin-coated circuit and 50% reduction of heparin dose. Scand J Thorac Cardiovasc Surg 1992;26:177-185.
8. Koul B, Wetterberg T, Ohqvist G, Olsson P. Veno-venous extracorporeal membrane oxygenation with a heparin-coated system in adult respiratory distress syndrome. Scand J Thorac Cardiovasc Surg 1991;25:199-206.
9. Koul B, Vesterqvist O, Egberg N, Steen NS. Twenty-four-hour heparin-free veno-right ventricular ECMO: an experimental study. Ann Thorac Surg 1992;53:1046-1051.
10. Larm O, Larsson R, Olsson P. A new non-thrombogenic surface prepared by selective covalent binding of heparin via a modified reducing terminal residue. Biomat Med Devic Artif Organs 1983;11:161-163.
11. Mottaghy K, Oedekoven B, Pöppel K, Bruchmuller K, Kovacs B, Spahn A, Geisen C. Heparin free long-term extracorporeal circulation using bioactive surfaces. Trans Am Soc Artif Inter Organs 1989;35:635-639.
12. Larsson R, Eriksson JC, Lagergren H, Olsson P. Platelet and plasma coagulation compatibility of heparinized and sulphated surfaces. Thromb Res 1979;15:157-167.
13. Gong J, Larsson R, Ekdhal KN, Mollnes T, Nilsson U, Nilsson B. Tubing loops as a model for cardiopulmonary bypass circuits: both the biomaterial and the blood-gas interfaces induce complement activation in an in vitro model. J Clin Immunol 1996;16:223-230.
14. Elgue G, Sanchez J, Egberg N, Olsson P, Riesenfeld J. Effect of surface-immobilized heparin on the activation of adsorbed factor XII. Artif Organs 1993;17:721-726.
15. Cornelius RM, Brash JL. Identification of plasma proteins adsorbed to hemodialyser membranes from heparinized human plasma. J Biomater Sci Polymer Edn 1993;4:291-304.
16. Elgue G, Blombäck M, Olsson P, Riesenfeld J. On the mechanism of coagulation inhibition on surfaces with end point immobilized heparin. Thromb Haemostas 1993;70:289-293.
17. Pasche B, Elgue G, Olsson P, Riesenfeld J, Rasmuson A. Binding of antithrombin to immobilized heparin under varying flow conditions. Artif Organs 1991;15:481-491.
18. Sanchez J, Elgue G, Riesenfeld J, Olsson P. Control of contact activation on end-point immobilized heparin: the role of antithrombin and the specific antithrombin-binding sequence. J Biomed Mater Res 1995;29:655-661.
19. Blombäck M, Abildgaard U, van der Besselaar AMHP, Clementson KJ, Dahlbäck B, Exner T, Francis CW, Gaffney P, et al. Nomenclature of quantities and units in thrombosis and haemostasis (Recommendations 1993). Thromb Haemostas 1994;71:375-394.
20. Carlson TH, Atencio AC. Isolation and partial characterization of two distinct types of antithrombin III from rabbit. Thromb Res 1982;27:23-34.
21. Franzen LE, Svensson S, Larm O. Structural studies on the carbohydrate portion of human antithrombin III. J Biol Chem 1980;255:5090-5093.
22. Mizuochi T, Fujii J, Kurachi K, Kobata A. Structural studies of the carbohydrate moiety of human antithrombin III. Arch Biochem Biophys 1980;203:458-465.
23. Peterson CB, Blackburn MN. Isolation and characterization of an antithrombin III variant with reduced carbohydrate content and enhanced heparin binding. J Biol Chem 1985;260:610-615.
24. Revak SD, Cochrane CG. Hageman factor: its structure and modes of activation. Thromb Haemost 1976;35:570-575.
25. Bouma BN, Miles LA, Beretta G, Griffin JH. Human plasma prekallikrein. Studies of its activation by activated factor XII and its inactivation by diisopropyl phosphofluoridate. Biochemistry 1980;19:1151-1160.
26. Hojima Y, Pierce JV, Pisano JJ. Purification and characterization of multiple forms of human plasma prekallikrein. J Biol Chem 1985;269:400-406.
27. Bouma BN, Griffin JH. Human blood coagulation factor XI. Purification, properties and mechanism of activation by factor XII. J Biol Chem 1977;252:6432-6437.
28. Holmer E, Kurachi K, Söderström G. The molecular-weight dependence of the rate-enhancing effect of heparin on the inhibition of thrombin, factor Xa, factor XIa, factor XIIa and kallikrein by antithrombin. Biochem J 1981;193:395-400.
29. Olson ST, Bjork I, Shore JD. Kinetic characterization of heparin-catalyzed and uncatalyzed inhibition of blood coagulation proteinases by antithrombin. Methods Enzymol 1993;222:525-559.
30. Björk I, Jackson CM, Jörnvall H, Lavine KK, Nordling K, Salsgiver WJ. The active site of antithrombin-release of the same proteolytically cleaved form of the inhibitor from complexes with Factor IXa, Factor Xa and thrombin. J Biol Chem 1982; 257:2406-2411.
31. Björk I, Olson ST, Shore JD. Molecular mechanism of the accelerating effect of heparin on the reactions between antithrombin and clotting proteases. In: Lane D, Lindahl U, editors. Heparin-chemical and biological properties and clinical applications. London-Melbourne-Auckland: Edwards Arnolds; 1989. p 231.
32. Choay J. Structure and activity of heparin and its fragments: an overview. Semin Thromb Haemostas 1989;15:359-364.
33. Goosen MF, Sefton MV. Heparinized styrene-butadiene-styrene elastomers. J Biomed Mater Res 1979;13:347-364.
34. Gott VL, Whiffen JD, Valiathan SM. Graphite-benzalkonium-heparin coatings on plastics and metals. Ann NY Acad Sci 1968;146:21-29
35. Leininger RI, Cooper CW, Falb RD, Grode GA. Nonthrombogenic plastic surfaces. Science 1966;152:1625-1626.
36. Lindon J, Rosenberg R, Merrill E, Salzman E. Interaction of human platelets with heparinized agarose gel. J Lab Clin Med 1978;91:47-59.
37. Citarella F, Fedele G, Roem D, Fantoni E, Hack CE. The second exon-encoded factor XII region is involved in the interaction of factor XII with factor XI and does not contribute to the binding site for negatively charged surfaces. Blood 1998;92:4198-4206.
38. Pixley RA, Schmaier A, Colman RW. Effect of negatively charged activating compounds on inactivation of factor XIIa by Cl inhibitor. Arch Biochem Biophys 1987;256:490-498.
39. Revak SD, Cochrane CG, Bouma BN, Griffin JH. Surface and fluid phase activities of the two forms of activated Hageman factor produced during contact activation in plasma. J Exp Med 1978;147:719-729.
40. Sanchez J, Lundquist P, Elgue G, Larsson R, Olsson P. Measuring the degree of plasma contact activation induced by artificial materials. Thromb Res 2002;105:407-412.
41. Björk I, Olson ST, Sheffer RG, Shore JD. Binding of heparin to human high molecular weight kininogen. Biochemistry 1989; 28:1213-1221.
42. Olson ST, Francis AM, Sheffer R, Choay J. Parallel mechanism of high molecular weight kininogen action as a cofactor in kallikrein inactivation and prekallikrein activation reactions. Biochemistry 1993;32:12148-12159.
43. Zhao M, Abdel-Razek T, Sun MF, Gailani D. Characterization of a heparin binding site on the heavy chain of factor XI. J Biol Chem 1998;273:31153-31159.
44. Kiesel W, Fujikawa K, Davie EW. Activation of bovine factor VII (proconvertin) by factor XIIa (activated factor Hageman). Biochemistry 1977;16:4189-4194.
45. Reddigari S, Kaplan A. Cleavage of human high-molecular weight kininogen by purified kallikreins and upon contact activation of plasma. Blood 1988;71:1334-1340.
46. Höök M, Björk I, Hopwood J, Lindahl U. Anticoagulant activity of heparin: separation of high-activity and low-activity heparin species by affinity chromatography on immobilized antithrombin. FEBS Lett 1976;66:90-93.
47. Pasche B, Kodama K, Larm O, Olsson P, Swedenborg J. Thrombin inactivation on surfaces with covalently bonded heparin. Thromb Res 1986;44:739-748.
48. Björk I, Lindahl U. Mechanism of the anticoagulant action of heparin. Mol Cell Biochem 1982;48:161-182.